PointMan™ successfully enriches low-level mutations in DNA extracted from blood
EKF Diagnostics Holdings plc announces a major breakthrough for its PointMan™ technology for potential use in future cancer testing and treatment.
The first successful results of a collaboration between EKF Molecular Diagnostics and the Institute of Life Sciences at Swansea University have demonstrated the detection of gene mutations in blood from samples archived in the Wales Cancer Bank. The Company's PointMan technology was used to analyse the whole blood of cancer patients diagnosed with metastatic melanoma (skin cancer that has spread) enabling the identification of gene mutations associated with response to drug treatment.
Very importantly, the results observed for mutations in the gene BRAF were consistent with the formalin fixed paraffin embedded (FFPE) tissue samples. FFPE being the laboratory standard method to prepare all biopsy samples for pathology review in order to diagnose the cancer. These results have been confirmed by DNA sequencing which had failed to identify the mutations prior to sample enrichment through our PointMan technology.
Dr Ricardo Del Sol, Senior Lecturer, ILS Swansea University, commented: "These results are a clear indication of the potential for PointMan to enable the use of a blood sample to assess the mutation status of cancer patients. We look forward to continuing this important work with EKF Molecular to validate our findings."